Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HTH-type transcriptional repressor LfrR is a member of the TetR family of regulators, primarily identified and characterized in Mycobacterium smegmatis [1, 2]. It serves as the primary negative regulator of the lfrRA operon, which encodes the LfrA multidrug efflux pump, a major facilitator superfamily (MFS) transporter [2, 4]. In the absence of inducing signals, LfrR homodimers bind to a specific operator sequence in the promoter region, sterically hindering RNA polymerase and repressing transcription [2, 3]. This repression is relieved when LfrR binds to various small-molecule ligands, such as cationic dyes (e.g., ethidium bromide, acriflavine, proflavine) and certain antibiotics like fluoroquinolones [2, 3]. Ligand binding induces a conformational change that reduces the protein's affinity for DNA, leading to the overexpression of the LfrA pump and subsequent extrusion of toxic compounds from the cell [3, 4]. As a key mediator of intrinsic multidrug resistance in mycobacteria, LfrR is a significant target for studying bacterial adaptation and developing strategies to sensitize pathogens to existing antibiotics [1, 2]. Structural studies have revealed that LfrR possesses a high degree of conformational plasticity, allowing it to recognize a broad range of structurally diverse ligands [3]. Mutations in the lfrR gene can lead to constitutive expression of the efflux pump, further enhancing the multidrug-resistant phenotype of the bacteria [2]. Understanding the regulatory network of LfrR provides insights into the evolution of antibiotic resistance in clinically relevant mycobacteria like Mycobacterium tuberculosis [1, 4].
Ligand-induced dissociation from DNA leading to the induction of the LfrA multidrug efflux pump
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HTH-type transcriptional repressor LfrR (LfrR).